Abstract
Background: Protective role of epoxyeicosatrienoic acids (EETs) have been demonstrated in hypertension, acute ischemia/reperfusion (I/R) injury and postischemic heart failure (HF) progression. Their effects are limited by low bioavailability of endogenous EETs. Levels of EETs in tissue can be elevated by inhibition of EETs degrading enzyme soluble epoxid hydrolase (sEH) or administration of agonistic EETs analogues. Here, we examined the effect of EET analogue EET-A and sEH inhibitor cAUCB to acute I/R injury and HF progression in normotensive (HanSD) and Ren-2 transgenic hypertensive rat (TGR).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
